| Literature DB >> 32347308 |
Effat Abbasi Montazeri1,2, Sakineh Seyed-Mohammadi1,2,3, Aram Asarehzadegan Dezfuli2, Azar Dokht Khosravi1,2, Maryam Dastoorpoor4, Mitra Roointan2, Morteza Saki1,2,3.
Abstract
Today methicillin resistant coagulase-negative staphylococci (MR-CoNS) are important in terms of causing significant nosocomial infections. Besides, MR-CoNS are confirmed as the reservoir of SCCmec elements that carry mecA (methicillin-resistant) gene. Hence, the present study was designed to evaluate the susceptibility pattern, prevalence and diversity of SCCmec types I, II, III, and IV in MR-CoNS strains. In this cross-sectional study, 44 clinical isolates of MR-CoNS were identified using the cefoxitin disc method and further confirmation by polymerase chain reaction (PCR) amplification of the mecA gene. Antimicrobial susceptibility of isolates was investigated by disc diffusion. The identification of CoNS was done by amplification and sequencing of the tuf gene. Multiplex PCR method was done for the determination of SCCmec types. In the present study, the Staphylococcus epidermidis and Staphylococcus haemolyticus were the most predominant isolates with a prevalence of 45.4%. The highest resistance rates were observed against erythromycin (84.1%) and clindamycin (75%). Multiplex PCR revealed the SCCmec type I as the predominant type in the present study. Our study showed that there was no significant relationship between the presence of different types of SCCmec elements and resistance to antibiotics. The present study highlighted a frequent prevalence of MR-CoNS harboring SCCmec type genes in Ahvaz, southwest of Iran. Thus, the molecular typing and periodical monitoring of their drug resistance pattern should be considered in national stewardship programs to designing useful antibiotic prescription strategies.Entities:
Keywords: Coagulase-negative staphylococci; MR-CoNS; Methicillin resistance; SCCmec
Mesh:
Substances:
Year: 2020 PMID: 32347308 PMCID: PMC7214399 DOI: 10.1042/BSR20200847
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Primers used in the present study
| Primer | Oligonucleotide sequence (5′ to 3′) | Target | Product size (bp) | Reference |
|---|---|---|---|---|
| tuf-F | GCCAGTTGAGGACGTATTCT | 412 | [ | |
| tuf-R | CCATTTCAGTACCTTCTGGTAA | |||
| mecA-F | TCCAGATTACAACTTCACCAGG | 162 | [ | |
| mecA-R | CCACTTCATATCTTGTAACG | |||
| 1272F1 | GCCACTCATAACATATGGAA | 415 | [ | |
| 1272R1 | CATCCGAGTGAAACCCAAA | |||
| β | ATTGCCTTGATAATAGCCYTCT | 937 | [ | |
| α3 | TAAAGGCATCAATGCACAAACACT | |||
| IS1272 | CGTCTATTACAAGATGTTAAGGATAAT | 518 | [ | |
| ccrCR | CCTTTATAGACTGGATTATTCAAAATAT |
Distribution of 44 MR-CoNS isolates in clinical specimens and hospital wards
| Bacterial species | MR-CoNS | |||||
|---|---|---|---|---|---|---|
| No. (%) | 20 (45.5) | 20 (45.5) | 2 (4.5) | 1 (2.3) | 1 (2.3) | |
| Clinical specimens | Wound | 2 (4.5) | 3(6.8) | 0 (0) | 0 (0) | 1 (2.3) |
| Urine | 14 (31.8) | 13 (29.5) | 2 (4.5) | 1 (2.3) | 0 (0) | |
| Blood | 2 (4.5) | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) | |
| Catheter tip | 2 (4.5) | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) | |
| Sputum | 0 (0) | 2 (4.5) | 0 (0) | 0 (0) | 0 (0) | |
| Hospital wards | Women’s ward | 1 (2.3) | 2 (4.5) | 1 (2.3) | 0 (0) | 1 (2.3) |
| Men’s ward | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| ICU | 2 (4.5) | 3 (6.8) | 0 (0) | 0 (0) | 0 (0) | |
| Surgery | 3 (6.8) | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) | |
| OPD | 11 (25) | 12 (27.2) | 1 (2.3) | 1 (2.3) | 0 (0) | |
| NICU | 1 (2.3) | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) | |
| Nephrology | 1 (2.3) | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) | |
Antibiotic susceptibility profile of 44 MR-CoNS isolates
| Antibiotic | Number (%) | ||
|---|---|---|---|
| Susceptible | Intermediate | Resistant | |
| Rifampin | 11 (25) | 7 (15.9) | 26 (59.1) |
| Clindamycin | 9 (20.5) | 2 (4.5) | 33 (75) |
| Erythromycin | 4 (9.1) | 3 (6.8) | 37 (84.1) |
| Gentamycin | 15 (34.1) | 0 (0.0) | 29 (65.9) |
| Trimethoprim–sulfamethoxazole | 21 (47.7) | 0 (0.0) | 23 (52.3) |
| Ciprofloxacin | 13 (29.5) | 5 (11.4) | 26 (59.1) |
| Linezolid | 34 (77.3) | 0 (0.0) | 10 (22.7) |
| Synercid | 28 (63.6) | 1 (2.3) | 15 (34.1) |
Multidrug-resistance patterns of 44 MR-CoNS isolates
| Resistance pattern | Phenotypic resistance | Number of resistant MR-CoNS isolates (%) |
|---|---|---|
| 1 | Rif- Gm- ERY- CM- CP | 8 (18.8) |
| 2 | Rif- Gm- ERY- CM- CP- TS | 4 (9.1) |
| 3 | Gm- ERY- CM- CP- TS | 3 (6.8) |
| 4 | Gm- ERY- CM- CP- SYN | 2(4.5) |
| 5 | Rif- Gm- ERY- CM- CP- SYN | 2(4.5) |
| 6 | Rif- ERY- CM- LZD- SYN- TS | 2(4.5) |
| 7 | Rif- ERY- CM- LZD | 1(2.3) |
| 8 | Gm- ERY- CP- LZD | 1(2.3) |
| 9 | Rif- Gm- ERY- CM- SYN | 1(2.3) |
| 10 | Rif- ERY- CM- TS | 1(2.3) |
| 11 | Rif- Gm- ERY- CM- TS | 1(2.3) |
| 12 | Rif- Gm- CM- CP- TS | 1(2.3) |
| 13 | Gm- ERY- CM- CP- LZD- TS | 1(2.3) |
| 14 | ERY - SYN- TS | 1(2.3) |
| 15 | Gm- ERY- CM- SYN- TS | 1(2.3) |
| 16 | Rif- Gm- ERY- CM- Cp- TS- SYN | 1(2.3) |
| 17 | Rif- Gm- ERY- CM- LZD- TS- SYN | 1(2.3) |
| 18 | ERY- CM- CP- LZD- TS- SYN | 1(2.3) |
| 19 | Gm- ERY- CM- Cp- LZD- TS- SYN | 1(2.3) |
| 20 | Rif- Gm- ERY- CM- Cp- LZD- TS- SYN | 1(2.3) |
Abbreviations: CM, clindamycin; CP, ciprofloxacin; ERY, erytomycin; Gm, gentamycin; LZD, linezolid; Rif, rifampin; SYN, synercid; TS, trimethoprimsulfamethoxazole.
Distribution of SCCmec elements among 44 MR-CoNS isolates
| SCCmec type | Total No. (%) | |||||
|---|---|---|---|---|---|---|
| I | 20 (45.5) | 7 (15.9) | 11 (25) | 1 (2.3) | 0 (0) | 1 (2.3) |
| II | 1 (2.3) | 0 (0) | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) |
| III | 2 (4.5) | 1 (2.3) | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) |
| IV | 4 (9.1) | 4 (9.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| I and III | 5 (11.4) | 2 (4.5) | 3 (6.8) | 0 (0) | 0 (0) | 0 (0) |
| III and IV | 1 (2.3) | 0 (0) | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) |
| Lacking SCCmec I-IV | 11 (25) | 6 (13.6) | 3 (6.8) | 1 (2.3) | 1 (2.3) | 0 (0) |
Association between SCCmec types and antimicrobial resistance patterns of 44 MR-CoNS isolates
| Type of SCC | Rif No. (%) | Gm No. (%) | ERY No. (%) | CM No. (%) | CP No. (%) | LZD No. (%) | SYN No. (%) | TS No. (%) |
|---|---|---|---|---|---|---|---|---|
| I | 12 (27.2) | 14 (31.8) | 17(38.6) | 15 (34) | 11 (25) | 2 (4.5) | 6 (13.6) | 9 (20.4) |
| II | 0 (0) | 0 (0) | 1 (2.3) | 0 (0) | 0 (0) | 0 (0) | 1 (2.3) | 1 (2.3) |
| III | 2 (4.5) | 2 (4.5) | 2 (4.5) | 2 (4.5) | 1(2.3) | 0 (0) | 1 (2.3) | 1 (2.3) |
| IV | 2 (4.5) | 2 (4.5) | 3 (6.8) | 2 (4.5) | 2 (4.5) | 1 (2.3) | 2 (4.5) | 1 (2.3) |
| 0.385 | 0.651 | 0.919 | 0.459 | 0.675 | 0.330 | 0.261 | 0.453 |
Abbreviations: CM, clindamycin; CP, ciprofloxacin; ERY, erytomycin; Gm, gentamycin; LZD, linezolid; Rif, rifampin; SYN, synercid; TS, trimethoprim–sulfamethoxazole.